Bruce Silverstein, MD
Ophthalmology · Redding, CANPI 1255326476
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.0%), consulting fees and gifts — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 40.5% of the total. Reporting peaked in 2021 at $2,722 and has fallen 72.3% since, to $755 in 2025.
Across 91 payments — averaging $66.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$2K
- AbbVie$584
- Alcon$549
- Bausch & Lomb, A Division Of Bausch Health US, LLC$479
- Sun Pharmaceutical Industries Inc.$258
- Dompe US, Inc.$230
- plus $1K from 17 others
Across 77 payments — averaging $8932.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$372K
- Bausch & Lomb Americas Inc.$198K
- AbbVie$104K
- Glaukos Corporation$8K
- Sun Pharmaceutical Industries Inc.$4K
- Shire North American Group Inc$2K
- plus $108 from 1 others
What the payments were for
- Consulting fees$2,44341%
- Food & beverage$3,54859%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 3 | $2,434 |
| AbbVie(2 entities) | 21 | $584 |
| Alcon | 12 | $549 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $479 |
| Sun Pharmaceutical Industries Inc. | 3 | $258 |
| Dompe US, Inc. | 4 | $230 |
| Omeros Corporation | 6 | $179 |
| Tarsus Pharmaceuticals, Inc. | 1 | $159 |
| Astellas Pharma US Inc | 2 | $136 |
| Bausch & Lomb Americas Inc. | 2 | $133 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| Rayner Intraocular Lenses Limited | 5 | $112 |
| Biotissue Holdings Inc. | 3 | $109 |
| Glaukos Corporation | 3 | $97 |
| Harrow Eye, LLC | 1 | $96 |
| Amgen(2 entities) | 5 | $95 |
| Novartis | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Rxsight Inc | 2 | $46 |
| Bausch Health US, LLC | 1 | $43 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| NEW World Medical,inc. | 1 | $13 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,009 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 693 | $28,604 |
| LumiganBimatoprost | 39 | $22,363 |
| MieboPerfluorohexyloctane/Pf | 21 | $15,183 |
| RestasisCyclosporine | 11 | $14,350 |
| Prednisolone Acetate | 288 | $11,022 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $9,011 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $6,517 |
| Alphagan PBrimonidine Tartrate | 15 | $5,895 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 76 | $5,548 |
| Latanoprost | 445 | $5,498 |
| Brimonidine Tartrate | 104 | $4,522 |
| IlevroNepafenac | 12 | $3,940 |
| ValacyclovirValacyclovir Hcl | 47 | $2,934 |
| Difluprednate | 20 | $2,911 |
| Timolol Maleate | 191 | $2,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $584 | $51,62098 claims |
| Bausch & Lomb Americas Inc.Miebo | $133 | $15,18321 claims |
| NovartisIlevro | $53 | $3,94012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Redding
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.